Abvc Biopharma (ABVC) Receivables - Accured (2012 - 2022)

Abvc Biopharma's (ABVC) quarterly Receivables - Accured came in at $81404.0 in Q3 2022, up 3401.25% on a QoQ basis from $2325.0 in Q4 2021.

Abvc Biopharma (ABVC) Receivables - Accured (2012 - 2022) Analysis & Trends

Abvc Biopharma (ABVC) has 5 years of Receivables - Accured data on file, last reported at $81404.0 in Q3 2022.

Quarterly Receivables - Accured changed N/A year-over-year to $81404.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $81404.0 (changed N/A YoY) and the FY2021 annual result came in at $2325.0, up 78.57% from the prior year.
Receivables - Accured rose to $81404.0 in Q3 2022, from $2325.0 in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of $81404.0 in Q3 2022 to a low of $1302.0 in Q4 2020.
A 4-year average of $28124.5 and a median of $14896.0 in 2018 frame the typical range for Receivables - Accured.
The widest YoY moves for Receivables - Accured: up 78.57% in 2021, down 78.57% in 2021.
Tracing ABVC's Receivables - Accured over 4 years: stood at $27467.0 in 2018, then plunged by 95.26% to $1302.0 in 2020, then soared by 78.57% to $2325.0 in 2021, then soared by 3401.25% to $81404.0 in 2022.
The last three Receivables - Accured figures came in at $81404.0 (Q3 2022), $2325.0 (Q4 2021), and $1302.0 (Q4 2020), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Abvc Biopharma	23.19 Mn	23.19 Mn	-	-

Download Data